{
    "nctId": "NCT00777101",
    "briefTitle": "Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer",
    "officialTitle": "A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 233,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Stage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancer\n* Prior use of Herceptin (trastuzumab), and a taxane\n* Adequate cardiac and renal function\n\nExclusion Criteria:\n\n* More than 2 prior Herceptin (trastuzumab) regimens or prior use of Xeloda (capecitabine) and / or Tykerb (lapatinib) \\[Tyverb\\]\n* Bone as the only site of disease\n* Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)\n* Significant gastrointestinal disorder with diarrhea as major symptom",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}